GLP1R and diabetes mellitus: These drugs are increasingly recognized to have multiple effects beyond lowering blood glucose, some of which may contribute to clinical practice in the treatment of cardiovascular diseases (10–13), SGLT-2i and GLP-1 RA are also included in the guidelines as a recommended drug for patients with diabetes and at high risk for cardiovascular events (14, 15).